Targeted Therapy for Treatment-Naive RET Fusion-Positive Lung Cancers
b'Guest: Alexander Drilon, MD
\\n\\n\\n \\n
This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).
'